Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26225205 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3GRM4CA2 | |
| SCHEMBL640001 | 0.73 | CA9 (0.35) | CA2CA9 | |
| SCHEMBL8924383 | 0.69 | CDK2 (0.33) | CA2CA9 | |
| SCHEMBL12059117 | 0.61 | CA9 (0.40) | CA2CA9 | |
| SCHEMBL24776682 | 0.60 | CA9 (0.35) | CA2CA9 | |
| SCHEMBL2998144 | 0.59 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24132855 | 0.57 | CA9 (0.33) | CA2CA9 | |
| SCHEMBL30480962 | 0.57 | CA9 (0.33) | CA2CA9 | |
| SCHEMBL23518159 | 0.57 | CA9 (0.41) | CA2CA9 | |
| SCHEMBL12041250 | 0.57 | CA9 (0.33) | CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378425-B2 | (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-05-27 | — | — | US | claimed |
| EP-1491531-B1 | (1-INDANONE)-(1,2,3,6-TETRAHYDROPYRIDINE) DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20050124642-A1 | (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds | EISAI CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| US-7378425-B2 | (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| EP-1491531-B1 | (1-INDANONE)-(1,2,3,6-TETRAHYDROPYRIDINE) DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20050124642-A1 | (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds | EISAI CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124642-A1 | (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds | SIGMAR1, CHRM1, ACHE | SLC6A2 282/4885SLC6A4 360/4885SLC6A3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.